TYK Med­i­cines seeks to launch new EGFR drug in Chi­na with $74M Hong Kong IPO

A Chi­nese drug­mak­er claim­ing to one-up As­traZeneca’s block­buster EGFR in­hibitor is slat­ed to jump on the Hong Kong stock ex­change af­ter rais­ing about $74 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER